How will you rethink your treatment goals to help your patients with primary biliary cholangitis (PBC)?
Rethink your treatment of PBC by learning about PBC progression and ways to reduce the risk of liver transplant or death for your patients.2,3
This site is intended for US healthcare professionals.
Rethink your treatment of PBC by learning about PBC progression and ways to reduce the risk of liver transplant or death for your patients.2,3
Lowering prognostic markers can reduce risk and improve survival, but recent evidence demonstrates current ALP and bilirubin benchmarks may not be enough and updated information from the Global PBC Study Groupc could be considered2,3:
References:
1. Zhang LN, Shi TY, Shi XH, et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology. 2013;58(1):264-272. 2. Murillo Perez CF, Harms MH, Lindor KD, et al; the GLOBAL PBC Study Group. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115(7):1066-1074. 3. Murillo Perez CF, Hirschfield GM, Corpechot C, et al; the GLOBAL PBC Study Group. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther. 2019;50(10):1127-1136.